window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-64619718-7');
Vernalis Research2021-03-03T10:40:18+00:00

Welcome to Vernalis Research

We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.

Latest news

Ligand to Divest Vernalis Research Operations

October 12th, 2020|

Consideration includes $25 million cash payment plus Ligand retains economics on
completed partnerships and share of economics on current collaborations


SAN DIEGO, Calif. (October 12, 2020) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s […]

Next event

Speaker: Lee Walmsley

Our approach

Our established group of experienced scientists is based at our fully-equipped research laboratories in Cambridge, UK.

We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.

We have the experience and capabilities for progressing projects from concept to clinic. We have generated lead compounds on enzymes, protein-protein interactions and GPCRs, leading to pre-clinical candidates for Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A.

Our business model

We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck, PhoreMost, Taisho and Asahi Kasei Pharma, and we seek additional partnerships.

To find out more, please contact us.

Current partnerships